Natural variability of lung function in primary ciliary dyskinesia: longitudinal analysis from the PROVALF-PCD cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Kewei, Kant Avni, Boon Mieke, Borrelli Melissa, Constant Carolina, Castillo Corullon Silvia, Cutrera Renato, Dillenhöfer Stefanie, Eryılmaz Polat Sanem, Eralp Ela, Feyaerts Nathalie, Harris Amanda, Hogg Claire, Koerner-Rettberg Cordula, Kouis Panayiotis, Lombardi Enrico, Lorent Natalie, Marthin June K, Martinu Vendula, Moreno-Galdo Antonio, Morgan Lucy, Nielsen Kim, Omran Heymut, Ozcelik Ugur, Pohunek Petr, Robinson Phil, Rovira-Amigo Sandra, Santamaria Francesca, Schlegtendal Anne, Tamalet Aline, Thouvenin Guillaume, Ademhan Tural Dilber, Ullmann Nicola, Walker Woolf T, Yiallouros Panayiotis, Pearse Camille, Frauchiger Bettina, Kuehni Claudia E, Beydon Nicole, Latzin Philipp, Lucas Jane S, Rubbo Bruna
Аннотация
METHODS: PROVALF-PCD (Prospective Observational Multicentre Study on Variability of Lung Function in Stable PCD Patients) was a large international prospective cohort conducted in 2017-2019. We included patients aged ≥5 years who were clinically stable at two or more consecutive visits and provided spirometry-derived lung function measurements. To calculate the upper limit of normal (ULN), we fitted an unadjusted multilevel mixed-effect model, and to determine the absolute change in FEV1 z-scores, we calculated the coefficient of repeatability (CR). We performed sensitivity analyses by stratifying relative change by age (adults versus children), number of measurements (at least four), and time between measurements (<4 months apart).
RESULTS: We included 252 participants from 12 countries with confirmed or highly likely PCD. We included 1028 FEV1 measurements from patients in stable state. The ULN for relative change between two measurements of FEV1 was 25%. Test variability remained high in all sensitivity analyses. The CR was 1.88 FEV1 z-score.
CONCLUSIONS: Changes in intra-individual FEV1 >25% between visits in stable PCD patients lie beyond the expected test variability and therefore could be considered physiologically relevant. These findings inform the selection of end-points for pulmonary intervention trials in PCD, as they suggest that FEV1 is not a sensitive test for monitoring lung health in PCD.